Tufts Center for the Study of Drug Development

Add links
From Wikipedia, the free encyclopedia
Tufts Center for the Study of Drug Development
Formation1976 (1976)
FounderLouis Lasagna
TypeIndependent, Academic, Non-Profit Research Center
PurposeResearching drug development
Location
Director
Kenneth Getz
Websitecsdd.tufts.edu

The Tufts Center for the Study of Drug Development is an independent, academic, non-profit research center at Tufts University in Boston, dedicated to researching drug development. It was established in 1976 by American physician Louis Lasagna.[1] The Center develops and publishes information to help researchers, regulators, and policy makers in areas related to the pharmaceutical and biotechnology industries. In any given year, approximately 55% of Tufts CSDD's operating expenses are supported by grants from the private sector and 45% from the public sector.[2][3]

Research[edit]

The Center studies trends in the pharmaceutical industry, maintaining databases pertaining to investigational new drugs, approved drugs, biopharmaceuticals, fast-tracked drugs, and orphan drugs.[4] The Center provides this information with the aim to improve the efficiency of drug development, foster innovation, and increase patient access to medicines.[5]

Drug development costs[edit]

The center has published numerous studies estimating the cost of developing new pharmaceutical drugs. In 2001, researchers from the Center estimated that the cost of doing so was $802 million,[6] and in 2014, they released a study estimating that this amount had risen to nearly $2.6 billion.[3] The 2014 study was criticized by Medecins Sans Frontieres, which said it was unreliable because the industry's research and development spending is not made public.[7] Aaron Carroll of the New York Times also criticized the study, saying it "contains a lot of assumptions that tend to favor the pharmaceutical industry."[8] The center's 2016 estimate, published in the Journal of Health Economics, found the cost to have averaged $2.87 billion (in 2013 dollars).[9]

References[edit]

  1. ^ "History". Tufts Center for the Study of Drug Development.
  2. ^ "Financial Disclosure". Tufts Center for the Study of Drug Development.
  3. ^ a b Silverman, Ed (20 November 2014). "What Does It Cost to Develop a New Drug? Latest Study Says $2.6 Billion". Wall Street Journal. Retrieved 21 November 2014.
  4. ^ "Databases". Tufts Center for the Study of Drug Development.
  5. ^ "Research Platforms and Current Research Agenda". Tufts Center for the Study of Drug Development.
  6. ^ Pear, Robert (1 December 2001). "Research Cost For New Drugs Said to Soar". New York Times. Retrieved 21 November 2014.
  7. ^ Pierson, Ransdell (18 November 2014). "CORRECTED-Tufts says average new drug costs $2.6 bln to develop, critics wary". Reuters. Retrieved 21 November 2014.
  8. ^ Carroll, Aaron (19 November 2014). "$2.6 Billion to Develop a Drug? New Estimate Makes Questionable Assumptions". New York Times. Retrieved 25 November 2014.
  9. ^ Joseph A. DiMasi; Henry G. Grabowski; Ronald W. Hansen (2016). "Innovation in the pharmaceutical industry: New estimates of R&D costs" (PDF). Journal of Health Economics. 47: 20–33. doi:10.1016/j.jhealeco.2016.01.012. hdl:10161/12742. PMID 26928437.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Tufts_Center_for_the_Study_of_Drug_Development&oldid=1177949089"